Generic Drug Approvals Expected To Rise In 2005 Despite Level Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's 2005 budget request seeks funding at current-year level for the Office of Generic Drugs, which is "functioning properly," Deputy Commissioner Crawford testifies. A House appropriations subcommittee suggests increased focus on generics, rather than reimportation, could address cost issues.
You may also be interested in...
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar